ATTR-Amyloidosis.net

Does My Dad's Story Still Matter?

Sometimes I wonder whether my father’s experience with hereditary ATTR amyloidosis is still relevant.

That may sound strange coming from someone whose advocacy is rooted so deeply in what happened to him, but the amyloidosis landscape has changed dramatically since my dad, Jessie, was diagnosed in 2014.

When I hear that someone has been newly diagnosed today, I often feel more hope for them than they may be able to feel for themselves in that moment. There is greater awareness, more research, more treatment options, and more opportunity for this disease to be recognized earlier.

I am deeply grateful for that progress. But real talk, it still hurts.

My dad experience with ATTR amyloidosis was in a different era

By the time Dad was diagnosed with hereditary ATTR cardiomyopathy (hATTR-CM), he already had serious heart disease. ATTR-CM was far less recognized than it is today, and there was no FDA-approved disease-modifying treatment for it in the United States.

For Dad, outside of a clinical trial, diflunisal was essentially the only treatment option available for most of his illness. It was being used off-label because of its ability to stabilize transthyretin.

Tafamidis, the first FDA-approved treatment for ATTR cardiomyopathy, was approved in the United States on May 3, 2019. Dad died May 4, 2020, one year and one day later. He was able to take tafamidis for approximately the final year of his life. The irony of that timing.

By providing your email address, you are agreeing to our Privacy Notice and Terms of Use.

What if Dad had been diagnosed in a time when amyloidosis was more likely to be recognized earlier, before his heart disease had progressed as far as it had?

There is no way to know what would have changed. Earlier diagnosis and treatment cannot guarantee an outcome, but they may create more opportunity for a better one.

That is the part of progress people do not always talk about. You can be thankful for what is available now and still hurt over what was not available for someone you loved.

How my dad kept rallying through ATTR-CM

Dad fought hard, although I am careful with that language because people do not survive because they fight harder than someone else. Determination cannot cure amyloidosis.

Still, there was something about my dad’s will that I cannot separate from how I remember his illness.

He rallied so many times.

I remember my mother telling me about something one of his physicians had said. I no longer remember the exact words, but I remember what they meant: Dad had come through acute event after acute event, repeatedly surviving moments his doctors did not expect him to. That has always stayed with me.

Medicine had real limits during much of Dad’s illness, and somehow, he kept coming back. Those rallies gave us more time: more conversations, holidays, birthdays, and more time with my mother, his children, and his grandchildren.

That was not simply a clinical outcome. That was our life.

Why I struggle with the word 'story'

In advocacy spaces, we talk a lot about sharing our stories. I understand why, and I use that language too.

But sometimes the word “story” feels too small.

“Story” can sound almost fabled, like something that has already happened and now sits at a distance. It has a beginning, middle, and ending. You tell it, someone reads or hears it, and then it is done.

That is not how this feels to me. My father’s “story” is still my life.

His death changed the family I was born into. Relationships shifted after we lost him. I carry the same hereditary variant that caused his disease, so what happened to him is not only something I remember. There is still uncertainty about what this disease may someday mean for me.

And then there are my children.

They are growing up in a world with more knowledge and more choices than my father or I had, but hereditary disease still carries uncertainty. I do not know what their genetic futures will look like or what decisions they may someday face.

My father died, but hereditary amyloidosis did not simply leave our family when he did.

Maybe that is why the word “story” feels inadequate. It can make something sound finished when, for my family, it is not.

Featured Forum

View all responses caret icon

Why my dad's experience does not have to predict yours

The medical world Dad lived in is becoming increasingly unfamiliar to someone diagnosed today.

And I want that to be true.

I want amyloidosis to be recognized earlier. I want better diagnosis and better therapies to make parts of what happened to Dad less common.

Progress is supposed to make parts of older patient experiences obsolete. That does not make the lives of those patients obsolete.

When I hear about someone newly diagnosed today, I do not want my father’s experience to predict their future. I want them to have more options, earlier recognition, and more opportunity for a better outcome than Dad had.

And still, I will probably always wonder what some of that progress might have meant for him.

I can be grateful that another family has choices mine did not and still wish those choices had arrived in time for ours. Both are true.

So, does my father’s amyloidosis story still matter today?

I think it does, although maybe not because it is a story at all.

It matters because it was his life. It changed mine. And because this is hereditary amyloidosis, parts of what happened to him are still very much a part of what my family and others carry today.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The ATTR-Amyloidosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

Please read our rules before commenting.